Found this comment posted somewhere else, but why does Invivo's website call out this trial as 20 patients yet the last 10Q calls for "up to 30 patients".
Which one is it? Could the mindset of the FDA be 30 all along?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.